Dantrolene. Pharmacological and therapeutic aspects;Dantrolen. Pharmakologische und therapeutische aspekte

Anaesthesist

Volumn 52, Issue 3, 2003, Pages 238-245

  Gerbershagen, M U ^a   Fiege, M ^a   Krause, T ^a   Agarwal, K ^a   Wappler, F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Clinical aspects; Dantrolene; Ecstasy intoxication; Malignant hyperthermia; Neuroleptic malignant syndrome; Pharmacology; Spasticity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DANTROLENE; RYANODINE RECEPTOR;

ARTICLE; CALCIUM TRANSPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG MECHANISM; DRUG SOLUBILITY; HUMAN; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; SARCOPLASMIC RETICULUM; SPASTICITY;

DANTROLENE; DRUG INTERACTIONS; HALLUCINOGENS; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 0037361446     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-003-0461-7     Document Type: Article

References (40)

1. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Haudecoeur G, Adnet-Bonte CA, Saulnier F, Dupuis BA (1989) The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 33:676-680
2. Barnes MP (2001) Medical management of spasticity in stroke. Age Ageing 30 [Suppl 1]:13-16
3. Brandom, BW, Larach MG, The North American Malignant Hyperthermia Registry (2002) Reassessment of the safety and efficacy of dantrolene. Anesthesiology 96:A1199
4. Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA (1995) Incidence of malignant hyperthermia reactions in 2214 patients undergoing muscle biopsy. Can J Anaesth 42:281-286
5. Dershwitz M, Sreter FA (1990) Azumolene reverses episodes of malignant hyperthermia in susceptible swine. Anesth Analg 70:253-255
6. Driessen JJ, Wuis EW, Gielen MJ (1985) Prolonged vecuronium neuromuscular blockade in a patient receiving orally administered dantrolene. Anesthesiology 62:523-524
7. Durham JA, Gandolfi AJ, Bentley JB (1984) Hepatotoxicological evaluation of dantrolene sodium. Drug Chem Toxicol 7:23-40
8. Ellis KO, Bryant SH (1972) Excitation-contraction uncoupling in skeletal muscle by dantrolene sodium. Naunyn Schmiedebergs Arch Pharmacol 274:107-109
9. Ellis KO, Carpenter JF (1974) Mechanism of control of skeletal-muscle contraction by dantrolene sodium. Arch Phys Med Rehabil 55:362-369
10. Flewellen EH, Nelson PE, Jones WP, Arens JF, Wagner DL (1983) Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 59:275-280
11. Flucher BE, Conti A, Takeshima H, Sorrentino V (1999) Type 3 and type 1 ryanodine receptors are localized in triads of the same mammalian skeletal muscle fibers. J Cell Biol 146:621-630
12. Gerbershagen MU, Ito WD, Wappler F, Fiege M, Schulte am Esch J (2001) Malignes neuroleptisches Syndrom nach Haloperidolapplikation. Anaesthesist 50:329-332
13. Gurrera RJ (2002) Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 25:183-193
14. Harrison GG (1975) Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47:62-65
15. Henderson VW, Wooten GF (1981) Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 31:132-137
16. Hosoi E, Nishizaki C, Gallagher KL, Wyre HW, Matsuo Y, Sei Y (2001) Expression of the ryanodine receptor isoforms in immune cells. J Immunol 167:4887-4894
17. Karan SM, Lojeski EW (1996) Skeletal muscle is responsible for heat production in porcine malignant hyperthermia. Anesth Analg 83:1133-1134
18. Ketel WB, Kolb ME (1984) Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin 9:161-169
19. Kolb ME, Horne ML, Martz R (1982) Dantrolene in human malignant hyperthermia. Anesthesiology 56:254-262
20. Lucke JN, Hall GM, Lister D (1976) Porcine malignant hyperthermia. I: Metabolic and physiological changes. Br J Anaesth 48:297-304
21. McCarthy TV, Quane KA, Lynch PJ (2000) Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 15:410-417
22. Nelson TE, Flewellen EH (1979) Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia. Anesthesiology 50:118-122
23. Nelson TE, Lin M, Zapata-Sudo G, Sudo RT (1996) Dantrolene sodium can increase of attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications. Anesthesiology 84:1368-1379
24. Ørding H, Hedengran AM, Skovgaard LT (1991) Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol Scand 35:711-716
25. Parness J, Palnitkar SS (1995) Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J Biol Chem 270:18465-18472
26. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J (2002) Identification of the dantrolene binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 277:34918-34923
27. Protasi F (2002) Structural interaction between RYRs and DHPRs in calcium release units of cardiac and skeletal muscle cells. Front Biosci 7:650-658
28. Rosenberg MR, Green M (1989) Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med 149:1927-1931
29. Saltzman LS, Kates RA, Corke BC, Norfleet EA, Heath KR (1984) Hyperkalaemia and cardiovascular collapse after verapamil and dantrolene administered in swine. Anesth Analg 63:473-478
30. Schmidt CJ, Kehne JH (1990) Neurotoxicity of MDMA: neurochemical effects. Ann N Y Acad Sci 600:66S-680
31. Snyder HR Jr, Davis CS, Bickerton RK, Halliday RP (1967) 1-[(5-arylfurfurylidene)amino]hydantoins. A new class of muscle relaxants. J Med Chem 10:807-810
32. Sorensen EM, Acosta D (1985) Comparison of dantrolene sodium with erythromycin estolate using primary cultures of rat hepatocytes. Drug Chem Toxicol 8:219-237
33. Takeshima H (1993) Primary structure and expression from cDNAs of the ryanodine receptor. Ann N Y Acad Sci 707:165-177
34. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Müller CR, Treves S (2001) Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 10:2879-2887
35. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A (2001) Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 10:189-194
36. Wappler F, Schulte am Esch J, Olthoff D, Anetseder M, Roewer N, Schulte-Sasse U (2002) Leitlinie zur Therapie der malignen Hyperthermie. Anästhesiol Intensivmed 43:50-54
37. Webb C, Williams V (1993) Ecstasy intoxication: appreciation of complications and the role of dantrolene. Anaesthesia 48:542-543
38. Weingarten AE, Korsh JI, Neuman GG, Stern SB (1987) Postpartum uterine atony after intravenous dantrolene. Anesth Analg 66:269-270
39. Yamamoto T, El-Hayek R, Ikemoto N (2000) Postulated role of interdomain interaction within the ryanodine receptor in Ca2+ channel regulation. J Biol Chem 275:11618-11625
40. Zapata-Sudo G, Sudo RT, Carmo PL, Trachez MM (2002) Comparative effects of dantrolene and azumolene on the contractility of skeletal and cardiac muscles. Anesthesiology 96:A71